11. Hodgkin lymphoma

  1. Ross Pinkerton MB, BCh, BaO, MD Executive Director, Division of Oncology2,
  2. Ananth Shankar MD, FRCPCH Consultant in Paediatric and Adolescent Oncology3 and
  3. Katherine K. Matthay BA, MD Mildred V. Strouss Professor of Translational Oncology, Director, Pediatric Hematology-Oncology4
  1. Ross Pinkerton

Published Online: 8 MAY 2013

DOI: 10.1002/9781118625309.ch11

Evidence-Based Pediatric Oncology

Evidence-Based Pediatric Oncology

How to Cite

Pinkerton, R. (2013) Hodgkin lymphoma, in Evidence-Based Pediatric Oncology (eds R. Pinkerton, A. Shankar and K. K. Matthay), John Wiley & Sons, Ltd, Oxford. doi: 10.1002/9781118625309.ch11

Editor Information

  1. 2

    Royal Children's Hospital, Children's Health Queensland, Brisbane, QLD, Australia

  2. 3

    University College London Hospitals NHS Foundation Trust London, UK

  3. 4

    Department of Pediatrics, UCSF School of Medicine and, UCSF Benioff Children's Hospital, San Francisco, CA, USA

Author Information

  1. Royal Children's Hospital, Brisbane, QLD, Australia

Publication History

  1. Published Online: 8 MAY 2013
  2. Published Print: 20 MAY 2013

ISBN Information

Print ISBN: 9780470659649

Online ISBN: 9781118625309



  • chemotherapy;
  • combination therapy;
  • Hodgkin lymphoma (HL);
  • musculoskeletal (MSK) hypoplasia;
  • radiation therapy


Pediatric Hodgkin lymphoma (HL) is highly responsive to both chemotherapy and radiation therapy (RT), resulting in excellent survival that now exceeds 90%. The emergence of musculoskeletal (MSK) hypoplasia in young children treated for HL with full-dose radiation led to the early pediatric clinical trials whose goal was to prevent MSK hypoplasia by use of low-dose, limited-field radiation. The trials by Bayle-Weisgerber and Gehan evolved in an era prior to the universal use of chemotherapy in children with HL. Both groups evaluated chemotherapy in specific cohorts, but also attempted to understand the optimal field size for pediatric radiation therapy (RT). Perhaps the most important study of this era gave only low-dose RT for those with good response to therapy in their excellent comparison of mustine, vincristine, procar-bazine, prednisone (MOPP) versus MOPP/doxorubicin, bleomy-cin, vinblastine, dacarbazine (ABVD). Combination chemotherapy was highly effective but long-term risks associated with even low-dose radiation remain.